<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01449630</url>
  </required_header>
  <id_info>
    <org_study_id>14283</org_study_id>
    <secondary_id>I5W-EW-LBCA</secondary_id>
    <nct_id>NCT01449630</nct_id>
  </id_info>
  <brief_title>A Study of LY3031207 in Healthy Subjects</brief_title>
  <official_title>A Single-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3031207 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I study of LY3031207 in healthy subjects. The purposes of this study are to
      look at safety, how well the study drug is tolerated, and how much of the study drug gets
      into the blood stream and how long it takes the body to get rid of it when given to humans.
      Information about any side effects that may occur will also be collected. Subjects will
      participate in the study for approximately 3 months. This study is for research purposes only
      and is not intended to treat any medical condition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 24, 2011</start_date>
  <completion_date type="Actual">April 2, 2012</completion_date>
  <primary_completion_date type="Actual">April 2, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With 1 or More Drug Related Adverse Events (AE) or Any Serious AE</measure>
    <time_frame>Baseline, up to 4 months</time_frame>
    <description>AEs that were considered possibly related to study drug, in the opinion of the investigator, were reported. A summary of serious and all other non-serious AEs, regardless of possible drug relatedness, is located in the Reported Adverse Event module.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of LY3031207</measure>
    <time_frame>Predose, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 96, 144 hours post dose</time_frame>
    <description>AUC from time 0 to last timepoint (AUC0-tlast) with measurable concentration of LY3031207.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of LY3031207</measure>
    <time_frame>Predose, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 96, 144 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Percent Change From Baseline of Ex Vivo Whole Blood Prostaglandin E (PGE) Synthesis After Lipopolysaccharide (LPS) Stimulation</measure>
    <time_frame>Predose, 0.5, 1, 2, 8, 24 and 144 hours post dose.</time_frame>
    <description>The effect of LY3031207 on PGE synthesis in whole blood after ex vivo LPS stimulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Prostaglandin E(2) Metabolite (PGEM)</measure>
    <time_frame>0 to 2, 2 to 4, 4 to 6, 6 to 12 and 12 to 24 hours post dose</time_frame>
    <description>The participant's urine was collected during protocol-defined intervals and the PGE metabolite PGEM was assessed. PGEM results for each interval were then compared to the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Prostacyclin Metabolite (PGIM)</measure>
    <time_frame>0 to 2, 2 to 4, 4 to 6, and 6 to 12 hours post dose</time_frame>
    <description>The participant's urine was collected during protocol-defined intervals and the PGE metabolite PGIM was assessed. PGIM results for each interval were then compared to the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Thromboxane A Metabolite (TXAM)</measure>
    <time_frame>0 to 2, 2 to 4, 4 to 6, and 6 to 12 hours post dose</time_frame>
    <description>The participant's urine was collected during protocol-defined intervals and the PGE metabolite TXAM was assessed. TXAM results for each interval were then compared to the baseline value.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>LY3031207</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received escalating doses of 5 mg (milligrams), 25 mg, 75 mg, 225 mg, 450 mg and 900 mg of LY3031207 capsule orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo administered orally in up to two occasions separated by at least a 3 week wash-out period between each dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single 400mg dose of celecoxib administered orally on one occasion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3031207</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3031207</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Celecoxib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subjects agree to use a reliable method of birth control during the study and for
             3 months following the last dose of the investigational product

          -  Women not of child-bearing potential due to surgical sterilization (at least 6 weeks
             after surgical bilateral oophorectomy with or without hysterectomy or at least 6 weeks
             after tubal ligation) confirmed by medical history or menopause

          -  Menopausal women include women with either spontaneous amenorrhea for at least 12
             months, not induced by a medical condition such as anorexia nervosa and not taking
             medications during the amenorrhea that induced the amenorrhea (for example [e.g.],
             oral contraceptives, hormones, gonadotropin-releasing hormone, antiestrogens,
             selective estrogen receptor modulators, or chemotherapy) or spontaneous amenorrhea for
             6 to 12 months and a follicle-stimulating hormone level greater than 40
             milli-International Unit (mIU/mL)

          -  Overtly healthy based on the history and physical examinations as determined by the
             investigator

          -  Between body mass index (BMI) of 18.5 and 32.0 kilogram per meter squared (kg/m^2),
             inclusive

          -  Normotensive defined as supine systolic blood pressure (BP) &lt;140 of millimeter mercury
             (mmHg), and diastolic BP &lt;90 mmHg, without the use of any antihypertensives, or
             results that are judged to be not clinically significant by the Investigator. Blood
             pressure may be retested up to 2 additional times, under well rested conditions

          -  Clinical laboratory test results within normal reference range for the population or
             investigator site, or results with acceptable deviations that are judged to be not
             clinically significant by the investigator

          -  Ex vivo whole blood prostaglandin E(PGE) synthesis after lipopolysaccharide (LPS)
             stimulation of no less than 5 nanograms/milliliter (ng/mL).

          -  Are reliable and willing to make themselves available for the duration of the study
             and are willing to follow study procedures

          -  Have given written informed consent approved by Lilly and the ethical review board
             (ERB) governing the site

        Exclusion Criteria:

          -  Are currently enrolled in, have completed or discontinued within the last 30 days
             from, a clinical trial involving an investigational product or unapproved use of a
             drug with a short half-life, or within 5 half-life of an investigational product with
             a half-life longer than 5 days, or concurrently enrolled in any other type of medical
             research judged not to be scientifically or medically compatible with this study

          -  Have known allergies to LY3031207 or any components of the formulation, celecoxib or
             sulfonamides. Subjects with known aspirin allergy or allergic reaction to
             non-steroidal anti-inflammatory drugs (NSAIDs) should also be excluded

          -  Are persons who have previously completed or withdrawn from this study or any other
             study investigating LY3031207 and who have previously received the investigational
             product

          -  Have an abnormality in the 12-lead Electrocardiogram (ECG), including QTc interval
             with Bazett's correction &gt;450 millisecond (msec) for men and &gt;470 msec for women or an
             abnormality that, in the opinion of the investigator, increases the risks associated
             with participating in the study. Electrocardiogram may be repeated after 5 minutes
             resting quietly, if the subject's heart rate is &gt;75 beats per minute

          -  History of, within the last 2 years, or presence of active cardiovascular disease,
             including acute myocardial infarction, unstable angina, congestive heart failure,
             stroke, or transient ischemic attack

          -  Presence of clinically significant active bleeding or history of bleeding diathesis at
             the time of screening

          -  Presence of active peptic ulcer disease, Gastrointestinal (GI) bleeding, chronic
             gastritis, inflammatory bowel disease, chronic diarrhea, or positive H. pylori
             serology

          -  Evidence of hepatitis C and/or positive hepatitis C antibody

          -  Evidence of hepatitis B and/or positive hepatitis B surface antigen

          -  Evidence of other chronic liver disease, including chronic alcoholic disease;
             non-alcoholic steatohepatitis; recent (within 3 months of screening) history of acute
             viral hepatitis; or subjects with known Gilbert Syndrome

          -  History of active neuropsychiatric disease

          -  Evidence of human immunodeficiency virus (HIV) infection and/or positive HIV
             antibodies

          -  Have a significant history of or current other cardiovascular, respiratory (especially
             asthma and chronic obstructive pulmonary disease), hepatic, renal, GI, endocrine,
             hematological, or neurological disorders capable of significantly altering the
             absorption, metabolism, or elimination of drugs; of constituting a risk when taking
             the study medication; or of interfering with the interpretation of data. History of
             prior surgeries (at least 3 months prior to dosing), such as splenectomy,
             cholecystectomy, and appendectomy are not exclusionary

          -  Regularly use of known drugs of abuse and/or show positive findings on urinary drug
             screening

          -  Are women with a positive pregnancy test or women who are lactating

          -  Intended use of over-the-counter medications or prescription medication within 14 days
             prior to dosing, this includes but is not limited to antihypertensives, diuretics,
             antiplatelet or anticoagulant drugs, and antidepressants

          -  Any use of NSAIDs, celecoxib, aspirin or acetaminophen (at doses &gt;1 gram [gm] per day)
             within 14 days of screening

          -  Any use of herbal or dietary supplements, or grapefruit and/or grapefruit juice,
             Seville oranges, starfruit, or pomegranate within 14 days prior to dosing of study
             drug

          -  Have donated blood of more than 500 milliliter (mL) within the last month

          -  Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14
             units per week (females) or are unwilling to stop alcohol consumption for the duration
             of the study (1 unit = 12 ounce [oz] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz
             or 45 mL of distilled spirits).

          -  Subjects who smoke more than 10 cigarettes per day or are unwilling to follow the
             Clinical Research Unit (CRU) smoking rules

          -  Subjects with any major surgery within 30 days prior to screening or subjects with
             planned surgeries to occur during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri, 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>October 5, 2011</study_first_submitted>
  <study_first_submitted_qc>October 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2011</study_first_posted>
  <results_first_submitted>March 18, 2019</results_first_submitted>
  <results_first_submitted_qc>June 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 5, 2019</results_first_posted>
  <last_update_submitted>June 28, 2019</last_update_submitted>
  <last_update_submitted_qc>June 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>LY3031207</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Three period crossover study with three dosing cohorts. The interval between the initiation of each dosing cohort was approximately 1 week, and the washout time between each dosing period was approximately 3 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort I Sequence 1</title>
          <description>Participants received 5 mg LY3031207, Placebo and 400 mg Celecoxib as per the below dosing schedule.
Period 1: 5 mg LY3031207 , Period 2: Placebo, and Period 3: 400 mg Celecoxib</description>
        </group>
        <group group_id="P2">
          <title>Cohort I Sequence 2</title>
          <description>Participants received 5 mg LY3031207, 225 mg LY3031207 and 400 mg Celecoxib as per the below dosing schedule.
Period 1: 5 mg LY3031207, Period 2: 225 mg LY3031207 and Period 3: 400 mg Celecoxib</description>
        </group>
        <group group_id="P3">
          <title>Cohort I Sequence 3</title>
          <description>Participants received Placebo, 225 mg LY3031207 and 400 mg Celecoxib as per the below dosing schedule.
Period 1: Placebo, Period 2: 225 mg LY3031207 and Period 3: 400 mg Celecoxib</description>
        </group>
        <group group_id="P4">
          <title>Cohort II Sequence 1</title>
          <description>Participants received 25 mg LY3031207 and Placebo as per the below dosing schedule.
Period 1: 25 mg LY3031207, Period 2: Placebo and Period 3: Placebo</description>
        </group>
        <group group_id="P5">
          <title>Cohort II Sequence 2</title>
          <description>Participants received 25 mg LY3031207, 450 mg LY3031207 (Fed condition) and 450 mg LY3031207 (Fasted) as per the below dosing schedule.
Period 1: 25 mg LY3031207, Period 2: 450 mg LY3031207 (Fed) and Period 3: 450 mg LY3031207 (Fasted)</description>
        </group>
        <group group_id="P6">
          <title>Cohort II Sequence 3</title>
          <description>Participants received Placebo, 450 mg LY3031207 (Fed condition) and 450 mg LY3031207 (Fasted) as per the below dosing schedule.
Period 1: Placebo, Period 2: 450 mg LY3031207 (Fed) and Period 3: 450 mg LY3031207 (Fasted)</description>
        </group>
        <group group_id="P7">
          <title>Cohort III Sequence 1</title>
          <description>Participants received LY3031207 75 mg, Placebo and celecoxib as per the below dosing schedule.
Period 1: LY3031207 75 mg, Period 2: Placebo and Period 3: Celecoxib 400 mg</description>
        </group>
        <group group_id="P8">
          <title>Cohort III Sequence 2</title>
          <description>Participants received LY3031207 75 mg, LY3031207 900 mg and celecoxib as per the below dosing schedule.
Period 1: LY3031207 75 mg, Period 2: LY3031207 900 mg and Period 3: Celecoxib 400 mg</description>
        </group>
        <group group_id="P9">
          <title>Cohort III Sequence 3</title>
          <description>Participants received Placebo, LY3031207 900 mg and celecoxib as per the below dosing schedule.
Period 1: Placebo, Period 2: LY3031207 900 mg and Period 3: Celecoxib 400 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort I Sequence 1</title>
          <description>Participants received 5 mg LY3031207, Placebo and 400 mg Celecoxib as per the below dosing schedule.
Period 1: 5 mg LY3031207 , Period 2: Placebo, and Period 3: 400 mg Celecoxib</description>
        </group>
        <group group_id="B2">
          <title>Cohort I Sequence 2</title>
          <description>Participants received 5 mg LY3031207, 225 mg LY3031207 and 400 mg Celecoxib as per the below dosing schedule.
Period 1: 5 mg LY3031207, Period 2: 225 mg LY3031207 and Period 3: 400 mg Celecoxib</description>
        </group>
        <group group_id="B3">
          <title>Cohort I Sequence 3</title>
          <description>Participants received Placebo, 225 mg LY3031207 and 400 mg Celecoxib as per the below dosing schedule.
Period 1: Placebo, Period 2: 225 mg LY3031207 and Period 3: 400 mg Celecoxib</description>
        </group>
        <group group_id="B4">
          <title>Cohort II Sequence 1</title>
          <description>Participants received 25 mg LY3031207 and Placebo as per the below dosing schedule.
Period 1: 25 mg LY3031207, Period 2: Placebo and Period 3: Placebo</description>
        </group>
        <group group_id="B5">
          <title>Cohort II Sequence 2</title>
          <description>Participants received 25 mg LY3031207, 450 mg LY3031207 (Fed condition) and 450 mg LY3031207 (Fasted) as per the below dosing schedule.
Period 1: 25 mg LY3031207, Period 2: 450 mg LY3031207 (Fed) and Period 3: 450 mg LY3031207 (Fasted)</description>
        </group>
        <group group_id="B6">
          <title>Cohort II Sequence 3</title>
          <description>Participants received Placebo, 450 mg LY3031207 (Fed condition) and 450 mg LY3031207 (Fasted) as per the below dosing schedule.
Period 1: Placebo, Period 2: 450 mg LY3031207 (Fed) and Period 3: 450 mg LY3031207 (Fasted)</description>
        </group>
        <group group_id="B7">
          <title>Cohort III Sequence 1</title>
          <description>Participants received LY3031207 75 mg, Placebo and celecoxib as per the below dosing schedule.
Period 1: LY3031207 75 mg, Period 2: Placebo and Period 3: Celecoxib 400 mg</description>
        </group>
        <group group_id="B8">
          <title>Cohort III Sequence 2</title>
          <description>Participants received LY3031207 75 mg, LY3031207 900 mg and celecoxib as per the below dosing schedule.
Period 1: LY3031207 75 mg, Period 2: LY3031207 900 mg and Period 3: Celecoxib 400 mg</description>
        </group>
        <group group_id="B9">
          <title>Cohort III Sequence 3</title>
          <description>Participants received Placebo, LY3031207 900 mg and celecoxib as per the below dosing schedule.
Period 1: Placebo, Period 2: LY3031207 900 mg and Period 3: Celecoxib 400 mg</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="2"/>
            <count group_id="B7" value="2"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="2"/>
            <count group_id="B10" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With 1 or More Drug Related Adverse Events (AE) or Any Serious AE</title>
        <description>AEs that were considered possibly related to study drug, in the opinion of the investigator, were reported. A summary of serious and all other non-serious AEs, regardless of possible drug relatedness, is located in the Reported Adverse Event module.</description>
        <time_frame>Baseline, up to 4 months</time_frame>
        <population>All participants who received at least 1 dose of study drug or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg LY3031207</title>
            <description>5 milligrams (mg) LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O2">
            <title>25 mg LY3031207</title>
            <description>25 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O3">
            <title>75 mg LY3031207</title>
            <description>75 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O4">
            <title>225 mg LY3031207</title>
            <description>225 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O5">
            <title>450 mg LY3031207 Fed</title>
            <description>450 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O6">
            <title>450 mg LY3031207 Fasted</title>
            <description>450 mg LY3031207 administered orally as capsules as a single dose to participants who were fasted.</description>
          </group>
          <group group_id="O7">
            <title>900 mg LY3031207</title>
            <description>900 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Matched placebo capsules administered orally.</description>
          </group>
          <group group_id="O9">
            <title>400 mg Celecoxib</title>
            <description>400 mg Celecoxib administered orally as capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 1 or More Drug Related Adverse Events (AE) or Any Serious AE</title>
          <description>AEs that were considered possibly related to study drug, in the opinion of the investigator, were reported. A summary of serious and all other non-serious AEs, regardless of possible drug relatedness, is located in the Reported Adverse Event module.</description>
          <population>All participants who received at least 1 dose of study drug or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Non-Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of LY3031207</title>
        <description>AUC from time 0 to last timepoint (AUC0-tlast) with measurable concentration of LY3031207.</description>
        <time_frame>Predose, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 96, 144 hours post dose</time_frame>
        <population>Pharmacokinetic (PK) population: All participants who received at least 1 dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg LY3031207</title>
            <description>5 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O2">
            <title>25 mg LY3031207</title>
            <description>25 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O3">
            <title>75 mg LY3031207</title>
            <description>75 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O4">
            <title>225 mg LY3031207</title>
            <description>225 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O5">
            <title>450 mg LY3031207 Fed</title>
            <description>450 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O6">
            <title>450 mg LY3031207 Fasted</title>
            <description>450 mg LY3031207 administered orally as capsules as a single dose to participants who were fasted.</description>
          </group>
          <group group_id="O7">
            <title>900 mg LY3031207</title>
            <description>900 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of LY3031207</title>
          <description>AUC from time 0 to last timepoint (AUC0-tlast) with measurable concentration of LY3031207.</description>
          <population>Pharmacokinetic (PK) population: All participants who received at least 1 dose of study drug and had evaluable PK data.</population>
          <units>nanogram*hour per milliliter (ng*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3040" spread="31"/>
                    <measurement group_id="O2" value="13900" spread="65"/>
                    <measurement group_id="O3" value="40000" spread="32"/>
                    <measurement group_id="O4" value="151000" spread="28"/>
                    <measurement group_id="O5" value="171000" spread="54"/>
                    <measurement group_id="O6" value="116000" spread="73"/>
                    <measurement group_id="O7" value="348000" spread="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Maximum Concentration (Cmax) of LY3031207</title>
        <time_frame>Predose, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 96, 144 hours post dose</time_frame>
        <population>Pharmacokinetic (PK) population: all participants who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg LY3031207</title>
            <description>5 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O2">
            <title>25 mg LY3031207</title>
            <description>25 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O3">
            <title>75 mg LY3031207</title>
            <description>75 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O4">
            <title>225 mg LY3031207</title>
            <description>225 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O5">
            <title>450 mg LY3031207 Fed</title>
            <description>450 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O6">
            <title>450 mg LY3031207 Fasted</title>
            <description>450 mg LY3031207 administered orally as capsules as a single dose to participants who were fasted.</description>
          </group>
          <group group_id="O7">
            <title>900 mg LY3031207</title>
            <description>900 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Concentration (Cmax) of LY3031207</title>
          <population>Pharmacokinetic (PK) population: all participants who received at least one dose of study drug and had evaluable PK data.</population>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185" spread="35"/>
                    <measurement group_id="O2" value="818" spread="40"/>
                    <measurement group_id="O3" value="2060" spread="20"/>
                    <measurement group_id="O4" value="5610" spread="31"/>
                    <measurement group_id="O5" value="7780" spread="32"/>
                    <measurement group_id="O6" value="5670" spread="49"/>
                    <measurement group_id="O7" value="11300" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Percent Change From Baseline of Ex Vivo Whole Blood Prostaglandin E (PGE) Synthesis After Lipopolysaccharide (LPS) Stimulation</title>
        <description>The effect of LY3031207 on PGE synthesis in whole blood after ex vivo LPS stimulation.</description>
        <time_frame>Predose, 0.5, 1, 2, 8, 24 and 144 hours post dose.</time_frame>
        <population>All participants who received at least 1 dose of study drug or placebo with evaluable PGE data at the specific time points.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg LY3031207</title>
            <description>5 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O2">
            <title>25 mg LY3031207</title>
            <description>25 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O3">
            <title>75 mg LY3031207</title>
            <description>75 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O4">
            <title>225 mg LY3031207</title>
            <description>225 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O5">
            <title>450 mg LY3031207 Fed</title>
            <description>450 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O6">
            <title>450 mg LY3031207 Fasted</title>
            <description>450 mg LY3031207 administered orally as capsules as a single dose to participants who were fasted.</description>
          </group>
          <group group_id="O7">
            <title>900 mg LY3031207</title>
            <description>900 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Matched placebo capsules administered orally.</description>
          </group>
          <group group_id="O9">
            <title>400 mg Celecoxib</title>
            <description>400 mg Celecoxib administered orally as capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Percent Change From Baseline of Ex Vivo Whole Blood Prostaglandin E (PGE) Synthesis After Lipopolysaccharide (LPS) Stimulation</title>
          <description>The effect of LY3031207 on PGE synthesis in whole blood after ex vivo LPS stimulation.</description>
          <population>All participants who received at least 1 dose of study drug or placebo with evaluable PGE data at the specific time points.</population>
          <units>percentage change in PGE</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hours (hr)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.2" spread="32.9"/>
                    <measurement group_id="O2" value="-15.6" spread="26.4"/>
                    <measurement group_id="O3" value="33.0" spread="45.0"/>
                    <measurement group_id="O4" value="12.7" spread="64.0"/>
                    <measurement group_id="O5" value="42.7" spread="69.7"/>
                    <measurement group_id="O6" value="-85.1" spread="13.8"/>
                    <measurement group_id="O7" value="-43.1" spread="17.8"/>
                    <measurement group_id="O8" value="56.1" spread="97.9"/>
                    <measurement group_id="O9" value="-10.4" spread="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="43.5"/>
                    <measurement group_id="O2" value="-4.8" spread="67.7"/>
                    <measurement group_id="O3" value="24.6" spread="67.5"/>
                    <measurement group_id="O4" value="-16.8" spread="93.7"/>
                    <measurement group_id="O5" value="-83.8" spread="41.4"/>
                    <measurement group_id="O6" value="-92.9" spread="8.5"/>
                    <measurement group_id="O7" value="-93.7" spread="6.9"/>
                    <measurement group_id="O8" value="65.4" spread="116.8"/>
                    <measurement group_id="O9" value="-44.8" spread="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.3" spread="20.1"/>
                    <measurement group_id="O2" value="-45.5" spread="49.4"/>
                    <measurement group_id="O3" value="-47.0" spread="19.8"/>
                    <measurement group_id="O4" value="-79.2" spread="21.2"/>
                    <measurement group_id="O5" value="-104.9" spread="11.8"/>
                    <measurement group_id="O6" value="-96.4" spread="8.9"/>
                    <measurement group_id="O7" value="-83.3" spread="11.8"/>
                    <measurement group_id="O8" value="65.1" spread="106.6"/>
                    <measurement group_id="O9" value="-68.2" spread="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="41.0"/>
                    <measurement group_id="O2" value="-40.1" spread="25.4"/>
                    <measurement group_id="O3" value="-41.3" spread="35.9"/>
                    <measurement group_id="O4" value="-79.3" spread="6.6"/>
                    <measurement group_id="O5" value="-94.3" spread="13.9"/>
                    <measurement group_id="O6" value="-88.3" spread="13.5"/>
                    <measurement group_id="O7" value="-98.4" spread="3.8"/>
                    <measurement group_id="O8" value="76.9" spread="109.1"/>
                    <measurement group_id="O9" value="-63.1" spread="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="9"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.4" spread="153.9"/>
                    <measurement group_id="O2" value="8.7" spread="73.3"/>
                    <measurement group_id="O3" value="60.0" spread="84.3"/>
                    <measurement group_id="O4" value="-29.5" spread="NA">Not analyzed due to insufficient number of participants.</measurement>
                    <measurement group_id="O5" value="-76.8" spread="40.6"/>
                    <measurement group_id="O6" value="-54.1" spread="28.4"/>
                    <measurement group_id="O7" value="-88.8" spread="12.2"/>
                    <measurement group_id="O8" value="124.8" spread="139.3"/>
                    <measurement group_id="O9" value="-19.9" spread="60.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>144 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178.2" spread="96.5"/>
                    <measurement group_id="O2" value="24.3" spread="58.2"/>
                    <measurement group_id="O3" value="153.7" spread="70.9"/>
                    <measurement group_id="O4" value="131.1" spread="111.4"/>
                    <measurement group_id="O5" value="125.1" spread="104.6"/>
                    <measurement group_id="O6" value="48.0" spread="49.3"/>
                    <measurement group_id="O7" value="41.4" spread="101.1"/>
                    <measurement group_id="O8" value="159.1" spread="138.7"/>
                    <measurement group_id="O9" value="7.6" spread="76.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Prostaglandin E(2) Metabolite (PGEM)</title>
        <description>The participant's urine was collected during protocol-defined intervals and the PGE metabolite PGEM was assessed. PGEM results for each interval were then compared to the baseline value.</description>
        <time_frame>0 to 2, 2 to 4, 4 to 6, 6 to 12 and 12 to 24 hours post dose</time_frame>
        <population>All participants who received at least 1 dose of study drug or placebo with evaluable PGEM data at specific time points.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg LY3031207</title>
            <description>5 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O2">
            <title>25 mg LY3031207</title>
            <description>25 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O3">
            <title>75 mg LY3031207</title>
            <description>75 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O4">
            <title>225 mg LY3031207</title>
            <description>225 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O5">
            <title>450 mg LY3031207 Fed</title>
            <description>450 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O6">
            <title>450 mg LY3031207 Fasted</title>
            <description>450 mg LY3031207 administered orally as capsules as a single dose to participants who were fasted.</description>
          </group>
          <group group_id="O7">
            <title>900 mg LY3031207</title>
            <description>900 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Matched placebo capsules administered orally.</description>
          </group>
          <group group_id="O9">
            <title>400 mg Celecoxib</title>
            <description>400 mg Celecoxib administered orally as capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Prostaglandin E(2) Metabolite (PGEM)</title>
          <description>The participant's urine was collected during protocol-defined intervals and the PGE metabolite PGEM was assessed. PGEM results for each interval were then compared to the baseline value.</description>
          <population>All participants who received at least 1 dose of study drug or placebo with evaluable PGEM data at specific time points.</population>
          <units>percentage change in PGEM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 - 2 hr interval</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="35.8"/>
                    <measurement group_id="O2" value="18.5" spread="31.4"/>
                    <measurement group_id="O3" value="11.0" spread="40.6"/>
                    <measurement group_id="O4" value="-26.6" spread="25.9"/>
                    <measurement group_id="O5" value="17.3" spread="53.5"/>
                    <measurement group_id="O6" value="10.7" spread="32.7"/>
                    <measurement group_id="O7" value="-19.8" spread="36.4"/>
                    <measurement group_id="O8" value="5.8" spread="47.3"/>
                    <measurement group_id="O9" value="-14.6" spread="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 - 4 hr interval</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="39.4"/>
                    <measurement group_id="O2" value="-2.1" spread="43.4"/>
                    <measurement group_id="O3" value="5.8" spread="45.5"/>
                    <measurement group_id="O4" value="-45.2" spread="32.3"/>
                    <measurement group_id="O5" value="6.1" spread="66.3"/>
                    <measurement group_id="O6" value="29.6" spread="64.1"/>
                    <measurement group_id="O7" value="-12.0" spread="41.4"/>
                    <measurement group_id="O8" value="11.2" spread="32.1"/>
                    <measurement group_id="O9" value="-30.7" spread="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 - 6 hr interval</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="39.3"/>
                    <measurement group_id="O2" value="-1.5" spread="57.4"/>
                    <measurement group_id="O3" value="-22.1" spread="35.5"/>
                    <measurement group_id="O4" value="-44.2" spread="27.3"/>
                    <measurement group_id="O5" value="-9.2" spread="56.9"/>
                    <measurement group_id="O6" value="15.8" spread="50.8"/>
                    <measurement group_id="O7" value="-24.2" spread="39.4"/>
                    <measurement group_id="O8" value="6.3" spread="44.4"/>
                    <measurement group_id="O9" value="-32.3" spread="42.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 - 12 hr interval</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="40.9"/>
                    <measurement group_id="O2" value="-17.9" spread="56.4"/>
                    <measurement group_id="O3" value="-13.5" spread="42.5"/>
                    <measurement group_id="O4" value="-41.9" spread="23.7"/>
                    <measurement group_id="O5" value="-18.8" spread="42.5"/>
                    <measurement group_id="O6" value="-13.0" spread="38.0"/>
                    <measurement group_id="O7" value="-37.5" spread="26.2"/>
                    <measurement group_id="O8" value="2.9" spread="44.0"/>
                    <measurement group_id="O9" value="-36.8" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 - 24 hr interval</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="20.1"/>
                    <measurement group_id="O2" value="-32.6" spread="33.5"/>
                    <measurement group_id="O3" value="-12.9" spread="31.0"/>
                    <measurement group_id="O4" value="-37.9" spread="29.3"/>
                    <measurement group_id="O5" value="-26.9" spread="43.6"/>
                    <measurement group_id="O6" value="-7.3" spread="38.2"/>
                    <measurement group_id="O7" value="-43.6" spread="33.1"/>
                    <measurement group_id="O8" value="0.9" spread="32.8"/>
                    <measurement group_id="O9" value="-46.5" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Prostacyclin Metabolite (PGIM)</title>
        <description>The participant's urine was collected during protocol-defined intervals and the PGE metabolite PGIM was assessed. PGIM results for each interval were then compared to the baseline value.</description>
        <time_frame>0 to 2, 2 to 4, 4 to 6, and 6 to 12 hours post dose</time_frame>
        <population>All participants who received at least 1 dose of study drug or placebo with evaluable PGIM data at specific time points</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg LY3031207</title>
            <description>5 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O2">
            <title>25 mg LY3031207</title>
            <description>25 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O3">
            <title>75 mg LY3031207</title>
            <description>75 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O4">
            <title>225 mg LY3031207</title>
            <description>225 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O5">
            <title>450 mg LY3031207 Fed</title>
            <description>450 of LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O6">
            <title>450 mg LY3031207 Fasted</title>
            <description>450 mg LY3031207 administered orally as capsules as a single dose to participants who were fasted.</description>
          </group>
          <group group_id="O7">
            <title>900 mg LY3031207</title>
            <description>900 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Matched placebo capsules administered orally.</description>
          </group>
          <group group_id="O9">
            <title>400 mg Celecoxib</title>
            <description>400 mg Celecoxib administered orally as capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Prostacyclin Metabolite (PGIM)</title>
          <description>The participant's urine was collected during protocol-defined intervals and the PGE metabolite PGIM was assessed. PGIM results for each interval were then compared to the baseline value.</description>
          <population>All participants who received at least 1 dose of study drug or placebo with evaluable PGIM data at specific time points</population>
          <units>percentage change in PGIM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 0 - 2 hr interval</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="36.5"/>
                    <measurement group_id="O2" value="25.2" spread="41.9"/>
                    <measurement group_id="O3" value="-3.9" spread="27.4"/>
                    <measurement group_id="O4" value="11.7" spread="28.0"/>
                    <measurement group_id="O5" value="44.6" spread="44.3"/>
                    <measurement group_id="O6" value="137.2" spread="195.5"/>
                    <measurement group_id="O7" value="37.2" spread="30.1"/>
                    <measurement group_id="O8" value="-17.0" spread="24.2"/>
                    <measurement group_id="O9" value="-18.9" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 2 - 4 hr interval</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0" spread="64.3"/>
                    <measurement group_id="O2" value="30.5" spread="20.8"/>
                    <measurement group_id="O3" value="21.2" spread="35.4"/>
                    <measurement group_id="O4" value="33.1" spread="42.8"/>
                    <measurement group_id="O5" value="244.7" spread="147.6"/>
                    <measurement group_id="O6" value="174.1" spread="249.0"/>
                    <measurement group_id="O7" value="122.5" spread="114.3"/>
                    <measurement group_id="O8" value="6.2" spread="81.9"/>
                    <measurement group_id="O9" value="-44.6" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 4 - 6 hr interval</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" spread="66.1"/>
                    <measurement group_id="O2" value="19.3" spread="45.8"/>
                    <measurement group_id="O3" value="31.0" spread="52.0"/>
                    <measurement group_id="O4" value="72.1" spread="69.3"/>
                    <measurement group_id="O5" value="198.3" spread="80.0"/>
                    <measurement group_id="O6" value="186.7" spread="70.1"/>
                    <measurement group_id="O7" value="264.0" spread="114.3"/>
                    <measurement group_id="O8" value="28.3" spread="71.1"/>
                    <measurement group_id="O9" value="-25.6" spread="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 6 - 12 hr interval</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0" spread="45.1"/>
                    <measurement group_id="O2" value="52.1" spread="45.2"/>
                    <measurement group_id="O3" value="63.6" spread="19.1"/>
                    <measurement group_id="O4" value="71.7" spread="66.4"/>
                    <measurement group_id="O5" value="208.5" spread="78.8"/>
                    <measurement group_id="O6" value="190.0" spread="117.5"/>
                    <measurement group_id="O7" value="201.4" spread="141.9"/>
                    <measurement group_id="O8" value="57.5" spread="208.1"/>
                    <measurement group_id="O9" value="-12.1" spread="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Thromboxane A Metabolite (TXAM)</title>
        <description>The participant's urine was collected during protocol-defined intervals and the PGE metabolite TXAM was assessed. TXAM results for each interval were then compared to the baseline value.</description>
        <time_frame>0 to 2, 2 to 4, 4 to 6, and 6 to 12 hours post dose</time_frame>
        <population>All participants who received at least 1 dose of study drug or placebo with evaluable TXAM data at specific time points.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg LY3031207</title>
            <description>5 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O2">
            <title>25 mg LY3031207</title>
            <description>25 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O3">
            <title>75 mg LY3031207</title>
            <description>75 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O4">
            <title>225 mg LY3031207</title>
            <description>225 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O5">
            <title>450 mg LY3031207 Fed</title>
            <description>450 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O6">
            <title>450 mg LY3031207 Fasted</title>
            <description>450 mg LY3031207 administered orally as capsules as a single dose to participants who were fasted.</description>
          </group>
          <group group_id="O7">
            <title>900 mg LY3031207</title>
            <description>900 mg LY3031207 administered orally as capsules as a single dose.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Matched placebo capsules administered orally.</description>
          </group>
          <group group_id="O9">
            <title>400 mg Celecoxib</title>
            <description>400 mg Celecoxib administered orally as capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Thromboxane A Metabolite (TXAM)</title>
          <description>The participant's urine was collected during protocol-defined intervals and the PGE metabolite TXAM was assessed. TXAM results for each interval were then compared to the baseline value.</description>
          <population>All participants who received at least 1 dose of study drug or placebo with evaluable TXAM data at specific time points.</population>
          <units>percentage change in TXAM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 0 - 2 hr interval</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="10.2"/>
                    <measurement group_id="O2" value="-5.7" spread="9.6"/>
                    <measurement group_id="O3" value="0.9" spread="17.4"/>
                    <measurement group_id="O4" value="-11.3" spread="10.8"/>
                    <measurement group_id="O5" value="4.4" spread="13.8"/>
                    <measurement group_id="O6" value="25.2" spread="31.5"/>
                    <measurement group_id="O7" value="11.0" spread="24.7"/>
                    <measurement group_id="O8" value="-11.5" spread="22.6"/>
                    <measurement group_id="O9" value="-6.2" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 2 - 4 hr interval</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="16.1"/>
                    <measurement group_id="O2" value="-15.5" spread="7.7"/>
                    <measurement group_id="O3" value="19.7" spread="23.7"/>
                    <measurement group_id="O4" value="0.7" spread="22.1"/>
                    <measurement group_id="O5" value="40.4" spread="52.4"/>
                    <measurement group_id="O6" value="28.3" spread="58.3"/>
                    <measurement group_id="O7" value="106.2" spread="107.1"/>
                    <measurement group_id="O8" value="-17.4" spread="17.2"/>
                    <measurement group_id="O9" value="-25.4" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 4 - 6 hr interval</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="25.4"/>
                    <measurement group_id="O2" value="-16.5" spread="11.4"/>
                    <measurement group_id="O3" value="1.2" spread="16.9"/>
                    <measurement group_id="O4" value="-3.8" spread="16.4"/>
                    <measurement group_id="O5" value="29.4" spread="29.6"/>
                    <measurement group_id="O6" value="16.7" spread="25.2"/>
                    <measurement group_id="O7" value="88.5" spread="47.9"/>
                    <measurement group_id="O8" value="-18.3" spread="18.7"/>
                    <measurement group_id="O9" value="-33.3" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 6 - 12 hr interval</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="29.5"/>
                    <measurement group_id="O2" value="-15.7" spread="19.6"/>
                    <measurement group_id="O3" value="20.7" spread="23.2"/>
                    <measurement group_id="O4" value="8.0" spread="25.2"/>
                    <measurement group_id="O5" value="30.9" spread="29.6"/>
                    <measurement group_id="O6" value="9.0" spread="23.1"/>
                    <measurement group_id="O7" value="85.8" spread="85.9"/>
                    <measurement group_id="O8" value="13.1" spread="14.8"/>
                    <measurement group_id="O9" value="-19.8" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up To 4 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>5 mg LY3031207</title>
          <description>5 mg LY3031207 administered orally as capsules as a single dose.</description>
        </group>
        <group group_id="E2">
          <title>25 mg LY3031207</title>
          <description>25 mg LY3031207 administered orally as capsules as a single dose.</description>
        </group>
        <group group_id="E3">
          <title>75 mg LY3031207</title>
          <description>75 mg LY3031207 administered orally as capsules as a single dose.</description>
        </group>
        <group group_id="E4">
          <title>225 mg LY3031207</title>
          <description>225 mg LY3031207 administered orally as capsules as a single dose.</description>
        </group>
        <group group_id="E5">
          <title>450 mg LY3031207 Fed</title>
          <description>450 mg LY3031207 administered orally as capsules as a single dose.</description>
        </group>
        <group group_id="E6">
          <title>450 mg LY3031207 Fasted</title>
          <description>450 mg LY3031207 administered orally as capsules as a single dose to participants who were fasted before receiving drug.</description>
        </group>
        <group group_id="E7">
          <title>900 mg LY3031207</title>
          <description>900 mg LY3031207 administered orally as capsules as a single dose.</description>
        </group>
        <group group_id="E8">
          <title>Placebo</title>
          <description>Matched placebo capsules administered orally.</description>
        </group>
        <group group_id="E9">
          <title>400 mg Celecoxib</title>
          <description>400 mg Celecoxib administered orally as capsules.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gingival infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

